News

nLife Therapeutics receives USD 350,000 from The Michael J. Fox Foundation for Parkinson’s Research

nLife Therapeutics receives USD 350,000 from The Michael J. Fox Foundation for Parkinson’s Research The funding will...

Read more

Antisense compound may provide new Alzheimer's treatment

A new antisense compound developed by Saint Louis University scientists restored learning, memory and other behaviors in mice genetically engineered...

Read more

Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon?

Drugs called anti-sense oligonucleotides, or ASOs, are one way of silencing the gene that causes Huntington’s disease. A new publication in...

Read more
Cabecera
 
Parkinson
Alzheimer
Huntington

Neuronal-focused Therapies
for a Healthy Life

nLife Therapeutics

  • nLife Therapeutics is a biopharmaceutical company leading the discovery and development of neuronal specific oligonucleotides (nOligos)  as therapeutic agents for CNS disorders.
  • nLife Therapeutics provides a unique oligonucleotide delivery platform with strong IP protection targeting several neurodegenerative conditions
  • Lead Candidate (NLF-PD-1233) is a First in Class Disease modifying oligonucleotide treatment for Parkinson Disease
  • Programs targeting: Huntington, Alzheimer Disease, DucheneDisease, Neuro-inflammation, MDD and Obesity are also underway
 
Pipeline
Platform
 
Ministerio de Ciencia e Innovación: MICINN
Ministerio de Industria y Competitividad: MINECO
Centro para el Desarrollo Tecnológico e Industiral: CDTI
Unión Europea con el emblema de FEDER
Xunta de Galicia
Michael J. Fox Foundation